Patent · US Active

Formulation of human antibodies for treating TNF-α associated disorders

US8802102B2 · kind B2 · utility

20Cited by

41References

29Claims

0Family size

Assignee

AbbVie Biotechnology Ltd. · BM

Inventors

Hans-Juergen Krause · Havelsee, DE
Lisa Baust · Ludwigshafen, DE
Michael Dickes · Rödersheim-Gronau, DE

Key dates

Filing date	Jan 3, 2014
Grant date	Aug 12, 2014
Priority date	—
Expiry date	Jan 3, 2034

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.